{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(3)"],"submitter":["Mass H"],"pubmed_abstract":["<h4>Objective</h4>Intra-articular injections (IAI) are commonly used to treat knee pain in persons with knee osteoarthritis (OA). We sought to determine the value of commonly used IAIs in knee OA management.<h4>Methods</h4>We used the validated Osteoarthritis Policy Model (OAPol) to assess the value of saline, corticosteroid (CS), hyaluronic acid (HA), and platelet-rich plasma (PRP) IAIs in knee OA management. We conducted a meta-analysis of high quality studies to estimate IAI-specific pain reduction. We assumed that repeat CS injections increase the risk of OA progression threefold in the base case. We determined the value of specific IAIs with incremental cost-effectiveness ratios (ICERs). We conducted sensitivity analyses to account for uncertainty in input parameters.<h4>Results</h4>I"],"journal":["Osteoarthritis and cartilage open"],"pagination":["100641"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12284352"],"repository":["biostudies-literature"],"pubmed_title":["Intra-articular injections for knee osteoarthritis management: Analysis of cost-effectiveness."],"pmcid":["PMC12284352"],"pubmed_authors":["Neogi T","Messier SP","Losina E","Jones MH","Tsai L","Katz JN","Collins JE","Yang C","Hunter DJ","Mass H"],"additional_accession":[]},"is_claimable":false,"name":"Intra-articular injections for knee osteoarthritis management: Analysis of cost-effectiveness.","description":"<h4>Objective</h4>Intra-articular injections (IAI) are commonly used to treat knee pain in persons with knee osteoarthritis (OA). We sought to determine the value of commonly used IAIs in knee OA management.<h4>Methods</h4>We used the validated Osteoarthritis Policy Model (OAPol) to assess the value of saline, corticosteroid (CS), hyaluronic acid (HA), and platelet-rich plasma (PRP) IAIs in knee OA management. We conducted a meta-analysis of high quality studies to estimate IAI-specific pain reduction. We assumed that repeat CS injections increase the risk of OA progression threefold in the base case. We determined the value of specific IAIs with incremental cost-effectiveness ratios (ICERs). We conducted sensitivity analyses to account for uncertainty in input parameters.<h4>Results</h4>I","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-03-16T04:44:17.58Z","creation":"2025-08-15T03:06:15.27Z"},"accession":"S-EPMC12284352","cross_references":{"pubmed":["40703537"],"doi":["10.1016/j.ocarto.2025.100641"]}}